Amendment Pursuant to 37 C.F.R. § 1.121

IN THE CLAIMS:

The claims set forth below with amendments as indicated will replace all prior versions and listing of claims in the application.

NE/I
D.K. ent
ec. 12/21/06
Correction

1. **(previously presented)** A compound in the form of an enantiomer (1*R*,2*R*) or (1*S*,2*S*) or in the form of a threo diastereoisomer, corresponding to general formula (I)



(I)

in which A represents

a group of general formula N-R_1, a group of general formula $N^+(O^-)R_1$ or a group of general formula $N^+(R')R_1$, and in which R_1 represents either a hydrogen atom, or a linear or branched (C_1-C_7)alkyl group optionally substituted with one or more fluorine atoms, or a (C_4-C_7)cycloalkyl group, or a (C_3-C_7)cycloalkyl(C_1-C_3)alkyl group, or a phenyl(C_1-C_3)alkyl group optionally substituted with one or two hydroxyl or methoxy groups, or a (C_2-C_4)alkenyl group, or a (C_2-C_4)alkynyl group,

R' represents a linear or branched (C_1-C_7)alkyl group,

X represents a hydrogen atom or one or more substituents chosen from halogen atoms and trifluoromethyl, linear or branched (C_1-C_4)alkyl and (C_1-C_4)alkoxy groups,

R_2 represents either a hydrogen atom, or one or more substituents chosen from halogen atoms and trifluoromethyl, (C_1-C_4)alkyl or (C_1-C_4)alkoxy groups, or amino groups of general formula NR_3R_4 in which R_3 and R_4 each represent, independently of each other, a hydrogen atom or a (C_1-C_4)alkyl group, or form with the nitrogen atom carrying them a pyrrolidine, piperidine or morpholine ring, or a phenyl group optionally substituted with an atom or a group as defined for the symbol X above,

in the form of a free base or of an addition salt with an acid.

2. **(previously presented)** A compound according to Claim 1 wherein it has the configuration (1*S*,2*S*) and in that R_2 represents one or more halogen atoms or trifluoromethyl groups.

3. **(previously presented)** A compound according to Claim 1 wherein it has the configuration (1*R*,2*R*) and in that R_2 represents a halogen atom and an amino group of general formula NR_3R_4 as defined in Claim 1.

4. **(cancelled)**

11 5. **(previously presented)** A pharmaceutical composition comprising a compound according to Claim 1 combined with an excipient.

6. **(original)** 2-Chloro-*N*-[(*S*)-phenyl-[(2*S*)-piperidin-2-yl]methyl]-3-(trifluoromethyl)benzamide according to claim 1.

7. **(original)** 2-Chloro-*N*-[(*S*)-phenyl-[(2*S*)-piperidin-2-yl]methyl]-3-(trifluoromethyl)benzamide hydrochloride 1:1 according to claim 6.

12 8. **(original)** A pharmaceutical composition comprising a compound according to Claim 2 combined with an excipient.

13 9. **(original)** A pharmaceutical composition comprising a compound according to Claim 3 combined with an excipient.

14 10. **(original)** A pharmaceutical composition comprising a compound according to Claim 6 combined with an excipient.

15 11. **(original)** A pharmaceutical composition comprising a compound according to Claim 7 combined with an excipient.

12. - 16. **(cancelled)**

4 17. **(original)** A compound according to claim 1 wherein A represents a group of general formula N-R_1 in which R_1 represents either a hydrogen atom, or a linear or branched (C_1-C_7)alkyl group optionally substituted with one or more fluorine atoms and said compound in the form of a free base or of an addition salt with an acid.

5 18. **(original)** A compound according to claim 1 which is selected from the group consisting of:

- threo-2-chloro-*N*-[(1-ethylpiperidin-2-yl)phenylmethyl]-3-trifluoromethylbenzamide hydrochloride;
- threo-2-chloro-*N*-[(1-ethylpiperidin-2-yl)phenylmethyl]-3-trifluoromethylbenzamide;
- 2-chloro-*N*-[(1*S*)-[(2*S*)-1-methylpiperidin-2-yl]phenylmethyl]-3-trifluoromethyl-benzamide hydrochloride;
- 2-chloro-*N*-[(1*S*)-[(2*S*)-1-methylpiperidin-2-yl]phenylmethyl]-3-trifluoromethyl-benzamide;
- threo-4-amino-3-chloro-*N*-[(1-methylpiperidin-2-yl)phenylmethyl]-5-trifluoromethyl-benzamide hydrochloride;
- threo-4-amino-3-chloro-*N*-[(1-methylpiperidin-2-yl)phenylmethyl]-5-trifluoromethyl-benzamide;
- 4-amino-3-chloro-*N*-[(1*R*)-[(2*R*)-1-methylpiperidin-2-yl]phenylmethyl]-5-trifluoro-methylbenzamide hydrochloride;

- 4-amino-3-chloro-*N*-[(1*R*)-[(2*R*)-1-methylpiperidin-2-yl]phenylmethyl]-5-trifluoromethylbenzamide;

- threo-2-chloro-*N*-[phenyl(piperidin-2-yl)methyl]-3-trifluoromethylbenzamide hydrochloride;

- threo-2-chloro-*N*-[phenyl(piperidin-2-yl)methyl]-3-trifluoromethylbenzamide;

- 2-chloro-*N*-[(*S*)-phenyl-[(2*S*)-piperidin-2-yl]methyl]-3-(trifluoromethyl)benzamide hydrochloride;

- 2-chloro-*N*-[(*S*)-phenyl-[(2*S*)-piperidin-2-yl]methyl]-3-(trifluoromethyl)benzamide;

- 2-chloro-*N*-[[1-methyl-1-oxido-piperidin-2-yl](phenyl)methyl]-3-trifluoromethylbenzamide; and

- 2(*S*)-2[(1*S*)-[[2-chloro-3-(trifluoromethyl)benzoyl]amino](phenyl)methyl]-1,1-dimethylpiperidinium iodide or

a pharmaceutically acceptable salt thereof.

8 ~~19~~. **(original)** 2-chloro-*N*-[(1*S*)-[(2*S*)-1-methylpiperidin-2-yl]phenylmethyl]-3-trifluoromethylbenzamide according to claim 1.

9 ~~20~~. **(original)** 2-chloro-*N*-[(1*S*)-[(2*S*)-1-methylpiperidin-2-yl]phenylmethyl]-3-trifluoromethylbenzamide hydrochloride 1:1 according to claim 1.

10 ~~21~~. **(original)** 4-amino-3-chloro-*N*-[(1*R*)-[(2*R*)-1-methylpiperidin-2-yl]phenylmethyl]-5-trifluoromethylbenzamide hydrochloride 1:1 according to claim 1.

16 15 ~~22~~. **(original)** A pharmaceutical composition comprising a compound according to Claim ~~18~~ 5 combined with an excipient.

17 16 ~~23~~. **(original)** A pharmaceutical composition comprising a compound according to Claim ~~19~~ 8 combined with an excipient.

18 17 ~~24~~. **(original)** A pharmaceutical composition comprising a compound according to Claim ~~20~~ 9 combined with an excipient.

19 18 ~~25~~. **(original)** A pharmaceutical composition comprising a compound according to Claim ~~21~~ 10 combined with an excipient.

26. **(currently amended)** A method for the treatment of a ~~disorder associated with glyt1 glycine transporter~~ disorder selected from the group consisting of dementia, psychoses, schizophrenia, extrapyramidal symptoms induced by neuroleptics, anxiety, panic attacks, depression, obsessive compulsive disorder, alcohol abuse and migraine, comprising administering to a patient in need of said treatment an effective amount of a compound according to Claim 1.

27. **(currently amended)** A method for the treatment of a ~~disorder associated with glyt1 glycine transporter~~ disorder selected from the group consisting of dementia, psychoses, schizophrenia, extrapyramidal symptoms induced by neuroleptics, anxiety, panic attacks, depression, obsessive compulsive disorder, alcohol abuse and migraine, comprising administering to a patient in need of said treatment an effective amount of a compound according to Claim 2.

28. **(currently amended)** A method for the treatment of a ~~disorder associated with glyt1 glycine transporter~~ disorder selected from the group consisting of dementia, psychoses, schizophrenia, extrapyramidal symptoms induced by neuroleptics, anxiety, panic attacks, depression, obsessive compulsive disorder, alcohol abuse and migraine, comprising administering to a patient in need of said treatment an effective amount of a compound according to Claim 6.

29. **(currently amended)** A method for the treatment of a ~~disorder associated with glyt1 glycine transporter~~ disorder selected from the group consisting of dementia, psychoses, schizophrenia, extrapyramidal symptoms induced by neuroleptics, anxiety, panic attacks, depression, obsessive compulsive disorder, alcohol abuse and migraine, comprising administering to a patient in need of said treatment an effective amount of a compound according to Claim 7.

30. **(currently amended)** A method for the treatment of a ~~disorder associated with glyt1 glycine transporter~~ disorder selected from the group consisting of dementia, psychoses, schizophrenia, extrapyramidal symptoms induced by neuroleptics, anxiety, panic attacks, depression, obsessive compulsive disorder, alcohol abuse and migraine, comprising administering to a patient in need of said treatment an effective amount of a compound according to Claim 17.

31. **(currently amended)** A method for the treatment of a ~~disorder associated with glyt1 glycine transporter~~ disorder selected from the group consisting of dementia, psychoses, schizophrenia, extrapyramidal symptoms induced by neuroleptics, anxiety, panic attacks, depression, obsessive compulsive disorder, alcohol abuse and migraine, comprising administering to a patient in need of said treatment an effective amount of a compound according to Claim 18.

32. **(currently amended)** A method for the treatment of a ~~disorder associated with glyt1 glycine transporter~~ disorder selected from the group consisting of dementia, psychoses, schizophrenia, extrapyramidal symptoms induced by neuroleptics, anxiety, panic attacks, depression, obsessive compulsive disorder, alcohol abuse and migraine, comprising administering to a patient in need of said treatment an effective amount of a compound according to Claim 19.

33. **(currently amended)** A method for the treatment of a ~~disorder associated with glyt1 glycine transporter~~ disorder selected from the group consisting of dementia, psychoses, schizophrenia, extrapyramidal symptoms induced by neuroleptics, anxiety, panic attacks, depression, obsessive compulsive disorder, alcohol abuse and migraine, comprising administering to a patient in need of said treatment an effective amount of a compound according to Claim 20.

34. **(currently amended)** A method for the treatment of a ~~disorder associated with glyt2 glycine transporter~~ disorder selected from the group consisting of painful muscular contractures in rheumatology, spinal pathology, pain including neurogenic pain, rebellious algia, Parkinson's disease, epilepsy and sleep apnea, comprising administering to a patient in need of said treatment an effective amount of a compound according to Claim 1.

35. **(currently amended)** A method for the treatment of a ~~disorder associated with glyt2 glycine transporter~~ disorder selected from the group consisting of painful muscular contractures in rheumatology, spinal pathology, pain including neurogenic pain, rebellious algia, Parkinson's disease, epilepsy and sleep apnea, comprising administering to a patient in need of said treatment an effective amount of a compound according to Claim 3.

36. **(currently amended)** A method for the treatment of a ~~disorder associated with glyt2 glycine transporter~~ disorder selected from the group consisting of painful muscular contractures in rheumatology, spinal pathology, pain including neurogenic pain, rebellious algia, Parkinson's disease, epilepsy and sleep apnea, comprising administering to a patient in need of said treatment an effective amount of a compound according to Claim 17.

37. **(currently amended)** A method for the treatment of a ~~disorder associated with glyt2 glycine transporter~~ disorder selected from the group consisting of painful muscular contractures in rheumatology, spinal pathology, pain including neurogenic pain, rebellious algia, Parkinson's disease, epilepsy and sleep apnea, comprising administering to a patient in need of said treatment an effective amount of a compound according to Claim 18.

38. **(currently amended)** A method for the treatment of a ~~disorder associated with glyt2 glycine transporter~~ disorder selected from the group consisting of painful muscular contractures in rheumatology, spinal pathology, pain including neurogenic pain, rebellious algia, Parkinson's disease, epilepsy and sleep apnea, comprising administering to a patient in need of said treatment an effective amount of a compound according to Claim 21.